Better answers with Prolaris

Clearly and confidently understand which cancer treatment option is right for you.

Better answers with Prolaris

Clearly and confidently understand which cancer treatment option is right for you.

What is Prolaris? 

Prolaris is an advanced genetic test that combines tools like and with a personalized tumor score to determine how aggressive your prostate cancer is. Prolaris helps you decide which treatment option is best based on your cancer.

Is Prolaris right for me? 

Prolaris is for any untreated man with prostate cancer and helps you answer your most pressing questions like:

  • Am I safe for active surveillance or do I need treatment?
  • Is my cancer at risk of spreading?
  • What are my chances of surviving prostate cancer?
  • Can I benefit from adding hormone therapy (ADT) to radiation or can I safely avoid the side-effects of ADT?

65%

In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.1,2,3

2x

The Prolaris score is 2x more prognostic than PSA and Gleason score combined4

$0

97% of patients pay $0 out of pocket

Prolaris Patient story

“Prolaris gave me the ability to maintain the lifestyle that my wife and I have lived with for many years now.”

Tim Petracca

Prolaris Patient story

“Prolaris gave me the ability to maintain the lifestyle that my wife and I have lived with for many years now.”

Tim Petracca

Myriad is here for you

Contact our trusted advisors for personalized support.

Learn how genetic testing can provide better answers for the best prostate cancer treatment for you in our FREE Patient Testing Guide.

References:

  1. Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer:Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7
  2. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612- 618
  3. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; doi: 10.1016/j.urolonc.2018.03.011.
  4. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC 2012;106(6):1095-1099